Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 3/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.37 |
| ▸ | DRD2 | P14416 | 3/20 | 0.35 |
| ▸ | DRD3 | P35462 | 2/20 | 0.35 |
| ▸ | KRAS | P01116 | 5/20 | 0.33 |
| ▸ | SOS1 | Q07889 | 5/20 | 0.33 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.31 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.31 |
| ▸ | USP2 | O75604 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24932847 | 0.82 | DRD2 (0.38) | IDO1CYP2C9KCNH2DRD2DRD3 | |
| SCHEMBL25924497 | 0.82 | KRAS (0.34) | IDO1CYP2C9KCNH2DRD2DRD3 | |
| SCHEMBL25924254 | 0.76 | DRD2 (0.35) | IDO1CYP2C9KCNH2DRD2DRD3 | |
| SCHEMBL26042096 | 0.73 | KRAS (0.30) | KRASSOS1 | |
| SCHEMBL30506993 | 0.73 | KRAS (0.30) | KRASSOS1 | |
| SCHEMBL25315300 | 0.73 | KRAS (0.30) | KRASSOS1 | |
| SCHEMBL18236380 | 0.70 | DRD2 (0.54) | IDO1CYP2C9KCNH2DRD2SLC6A4 | |
| SCHEMBL25924619 | 0.68 | IDO1 (0.38) | IDO1CYP2C9KCNH2DRD2DRD3 | |
| SCHEMBL25924599 | 0.65 | IDO1 (0.30) | IDO1CYP2C9KCNH2 | |
| SCHEMBL26023928 | 0.63 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023141432-A2 | APOL1 INHIBITORS AND METHODS OF USE | MAZE THERAPEUTICS, INC. (US) | 2023-07-27 | — | — | WO | disclosed |